SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 7.57 |
| Enterprise Value ($M) | 5.68 |
| Book Value ($M) | 3.69 |
| Book Value / Share | 0.12 |
| Price / Book | 2.05 |
| NCAV ($M) | 1.83 |
| NCAV / Share | 0.06 |
| Price / NCAV | 4.13 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.83 |
| Return on Assets (ROA) | -1.38 |
| Return on Equity (ROE) | -3.61 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.51 |
| Current Ratio | 8.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.63 |
| Assets | 4.48 |
| Liabilities | 0.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Shares Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 4.90 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 129,462 | 466,002 | 27.78 | |
| 319,992 | 952,735 | 33.59 | |
| 279,519 | 1,038,716 | 26.91 | |
| 293,651 | 919,125 | 31.95 | |
| 993,337 | 2,856,773 | 34.77 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CAPR – Capricor Therapeutics, Inc. | CARA – Cara Therapeutics, Inc. |
| CASI – CASI Pharmaceuticals, Inc. | CDMO – Avid Bioservices, Inc. |
| CDTX – Cidara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io